Call us today for a free and confidential consultation with a Paul & Hanley LLP attorney.  We are one of the nation's leading toxic tort litigation firms  We'll discuss your specific case and give you honest answers to your questions.

Our toll-free number is (800) 933-2244.  The mesothelioma lawyers of Paul & Hanley look forward to helping you.

Northern California
1608 Fourth Street,
Suite 300
Berkeley, CA 94710
Phone: 510-559-9980
Fax: 510-559-9970
Map

Southern California
5716 Corsa Ave,
Suite 203
Westlake Village, CA 91362
Phone: 818-865-2807
Fax: 818-865-0805
Map

811 W. Seventh St.
Suite 206
Los Angeles, CA 90017
Phone: 213-689-3278
Fax: 213-689-4309
Map

Wisconsin
250 East Wisconsin Ave. 
Suite 1800
Milwaukee, WI 53202
Phone: 414-289-3135
Toll Free: 800-933-2244
 

 


Pleural, Peritoneal, and Tunica Vaginalis Mesothelioma Clinical Trial Using AZD2171

AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Last Modified: 4/6/2009     First Published: 3/24/2006  


Alternate Title

Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery

 

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentActive18 and overNCIUCCRC-14203B
NCI-7103, 7103, NCT00309946

Trial Description

Purpose:

AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

 

This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.

 

Eligibility:

Eligibility criteria include the following:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

 

Treatment/Intervention:

Patients will receive ADZ2171 by mouth once a day. Treatment may continue for as long as benefit is shown. Blood will be collected periodically for laboratory studies.

After finishing treatment, patients will be evaluated for up to 8 weeks.

 

Important:

For more details about this trial, refer to the Health Professional version 6 of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site 7.

 

Trial Contact Information

Trial Lead Organizations

University of Chicago Cancer Research Center

Hedy Kindler, MD, Principal investigator
Ph: 773-702-0360; 888-824-0200

Trial Sites

U.S.A.
California
 Beverly Hills
 
 
 
 Tower Cancer Research Foundation
 
 Philomena McAndrew, MD
Ph: 310-888-8680
  
 
 Duarte
 
 City of Hope Comprehensive Cancer Center
 
 Clinical Trials Office - City of Hope Comprehensive Cancer Center
Ph: 800-826-4673
  
 Email: becomingapatient@coh.org
 
 Los Angeles
 
 USC/Norris Comprehensive Cancer Center and Hospital
 
 Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital
Ph: 323-865-0451
  
 
 Martinez
 
 Contra Costa Regional Medical Center
 
 Sharon Hiner, MD
Ph: 925-370-5114
 800-232-4636
 Email: shiner@hsd.co.contra-costa.ca.us
 
 Pasadena
 
 City of Hope Medical Group
 
 Mark McNamara, MD
Ph: 626-396-2900
  
 Email: mmcnamara@ccsmg.com
 
 Sacramento
 
 University of California Davis Cancer Center
 
 Clinical Trials Office - University of California Davis Cancer Center
Ph: 916-734-3089
  
 
Illinois
 Chicago
 
 
 University of Chicago Cancer Research Center
 
 Clinical Trials Office - University of Chicago Cancer Research Center
Ph: 773-834-7424
  
 
 Decatur
 
 Decatur Memorial Hospital Cancer Care Institute
 
 Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute
Ph: 217-876-6601
  
 
 Evanston
 
 Evanston Hospital
 
 Clinical Trials Office - Evanston Hospital
Ph: 847-570-1381
  
 
 Harvey
 
 Ingalls Cancer Care Center at Ingalls Memorial Hospital
 
 Clinical Trials Office - Ingalls Cancer Care Center at Ingalls Memorial Hospital
Ph: 708-915-6747
  
 
 Maywood
 
 Cardinal Bernardin Cancer Center at Loyola University Medical Center
 
 Clinical Trials Office - Cardinal Bernardin Cancer Center
Ph: 708-226-4357
  
 
 Peoria
 
 Oncology Hematology Associates of Central Illinois, PC - Peoria
 
 Sachdev Thomas, MD
Ph: 309-243-1000
  
 Email: sthomas@ohaci.com
 
 Springfield
 
 Central Illinois Hematology Oncology Center
 
 Edem Agamah, MD, MS
Ph: 217-525-2500
  
 Email: ihdn@aol.com
 
Indiana
 Fort Wayne
 
 
 Fort Wayne Medical Oncology and Hematology
 
 David Sciortino, MD
Ph: 260-484-8830
 800-852-2333
 
 South Bend
 
 CCOP - Northern Indiana CR Consortium
 
 David Taber, MD
Ph: 574-647-3353
 800-284-7370
 
Michigan
 Saint Joseph
 
 
 Oncology Care Associates, PLLC
 
 Eric Lester, MD
Ph: 269-985-0029
  
 
Pennsylvania
 Hershey
 
 
 Penn State Cancer Institute at Milton S. Hershey Medical Center
 
 Clinical Trials Office - Penn State Cancer Institute at Milton S. Hershey Medical Center
Ph: 717-531-3779
  
 Email: CTO@hmc.psu.edu
 
Wisconsin
 Milwaukee
 
 
 Medical College of Wisconsin Cancer Center
 
 Clinical Trials Office - Medical College of Wisconsin Cancer Center
Ph: 414-805-4380
  
 
Canada
Ontario
 Toronto
 
 
 
 Princess Margaret Hospital
 
 Natasha Leighl, MD, FRCPC
Ph: 416-946-2399
  
 

 

Registry Information
Official Title Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma
Trial Start Date 2005-12-05
Trial Completion Date 2006-10-01 (estimated)
Registered in ClinicalTrials.gov NCT00309946 8
Date Submitted to PDQ 2005-12-09
Information Last Verified 2007-06-03
NCI Grant/Contract Number CM17102, CA14599

 



Glossary Terms

AZD2171
A substance being studied in the treatment of some types of cancer. AZD2171 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called cediranib and Recentin.
blood
A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.
brain metastasis (...meh-TAS-tuh-sis)
Cancer that has spread from the original (primary) tumor to the brain.
cell (sel)
The individual unit that makes up the tissues of the body. All living things are made up of one or more cells.
chemotherapy (KEE-moh-THAYR-uh-pee)
Treatment with drugs that kill cancer cells.
eligibility criteria (EH-lih-jih-BIH-lih-tee kry-TEER-ee-uh)
In clinical trials, requirements that must be met for an individual to be included in a study. These requirements help make sure that patients in a trial are similar to each other in terms of specific factors such as age, type and stage of cancer, general health, and previous treatment. When all participants meet the same eligibility criteria, it gives researchers greater confidence that results of the study are caused by the intervention being tested and not by other factors.
enzyme (EN-zime)
A protein that speeds up chemical reactions in the body.
malignant mesothelioma (muh-LIG-nunt MEH-zoh-THEE-lee-OH-muh)
A rare type of cancer in which malignant cells are found in the lining of the chest or abdomen. Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.
measurable disease
A tumor that can be accurately measured in size. This information can be used to judge response to treatment.
phase II trial
A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.
radiation therapy (RAY-dee-AY-shun THAYR-uh-pee)
The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood to tissues throughout the body. Also called irradiation and radiotherapy.
surgery (SER-juh-ree)
A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.
tumor (TOO-mer)
An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Tumors may be benign (not cancer), or malignant (cancer). Also called neoplasm.


Table of Links

1http://www.cancer.gov/clinicaltrials/learning
2http://www.cancer.gov/cancertopics/factsheet/Information/clinical-trials
3http://www.cancer.gov/clinicaltrials/learning/questions-to-ask-about-participat
ing
4http://www.nlm.nih.gov/medlineplus/druginformation.html
5http://www.cancer.gov/clinicaltrials/UCCRC-14203B#EntryCriteria_CDR0000463521
6http://www.cancer.gov/clinicaltrials/UCCRC-14203B
7http://cancer.gov/clinicaltrials
8http://clinicaltrials.gov/ct/show/NCT00309946